222 related articles for article (PubMed ID: 31298750)
1. Frontline treatment of elderly non transplant-eligible multiple myeloma patients using CyBorD with or without thalidomide-based consolidation: a retrospective multi-centre analysis of real-world data.
Chan H; Chai K; Shih S; Lewsey R; Chen K; McDiarmid B; Jackson S; Simpson D
Br J Haematol; 2019 Nov; 187(4):470-477. PubMed ID: 31298750
[TBL] [Abstract][Full Text] [Related]
2. Real world outcomes with Bortezomib Thalidomide dexamethasone and Cyclophosphamide Bortezomib dexamethasone induction treatment for transplant eligible multiple myeloma patients in a Latin American country. A Retrospective Cohort Study from Grupo Argentino de Mieloma Múltiple.
Schütz NP; Ochoa P; Duarte P; Remaggi G; Yantorno S; Corzo A; Zabaljauregui S; Shanley C; Lopresti S; Orlando S; Verri V; Quiroga L; García CA; Fernández V; Fantl D
Hematol Oncol; 2020 Aug; 38(3):363-371. PubMed ID: 32196120
[TBL] [Abstract][Full Text] [Related]
3. Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study.
Tacchetti P; Pantani L; Patriarca F; Petrucci MT; Zamagni E; Dozza L; Galli M; Di Raimondo F; Crippa C; Boccadoro M; Barbato S; Tosi P; Narni F; Montefusco V; Testoni N; Spadano A; Terragna C; Pescosta N; Marzocchi G; Cellini C; Galieni P; Ronconi S; Gobbi M; Catalano L; Lazzaro A; De Sabbata G; Cangialosi C; Ciambelli F; Musto P; Elice F; Cavo M;
Lancet Haematol; 2020 Dec; 7(12):e861-e873. PubMed ID: 33242443
[TBL] [Abstract][Full Text] [Related]
4. Cyclophosphamide-bortezomib-dexamethasone compared with bortezomib-dexamethasone in transplantation-eligible patients with newly diagnosed multiple myeloma.
Figueiredo A; Atkins H; Mallick R; Kekre N; Kew A; McCurdy A
Curr Oncol; 2020 Apr; 27(2):e81-e85. PubMed ID: 32489256
[TBL] [Abstract][Full Text] [Related]
5. Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial.
Kim HJ; Yoon SS; Lee DS; Sohn SK; Eom HS; Lee JL; Chung JS; Kim K; Suh C; Won JH; Kim JS; Park JS; Kang HJ; Seong CM; Kim CS; Lee SJ; Lee JH
Ann Hematol; 2012 Feb; 91(2):249-56. PubMed ID: 21789621
[TBL] [Abstract][Full Text] [Related]
6. Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA): health-related quality of life outcomes of a randomised, open-label, phase 3 trial.
Roussel M; Moreau P; Hebraud B; Laribi K; Jaccard A; Dib M; Slama B; Dorvaux V; Royer B; Frenzel L; Zweegman S; Klein SK; Broijl A; Jie KS; Wang J; Vanquickelberghe V; de Boer C; Kampfenkel T; Gries KS; Fastenau J; Sonneveld P
Lancet Haematol; 2020 Dec; 7(12):e874-e883. PubMed ID: 33242444
[TBL] [Abstract][Full Text] [Related]
7. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study.
Moreau P; Attal M; Hulin C; Arnulf B; Belhadj K; Benboubker L; Béné MC; Broijl A; Caillon H; Caillot D; Corre J; Delforge M; Dejoie T; Doyen C; Facon T; Sonntag C; Fontan J; Garderet L; Jie KS; Karlin L; Kuhnowski F; Lambert J; Leleu X; Lenain P; Macro M; Mathiot C; Orsini-Piocelle F; Perrot A; Stoppa AM; van de Donk NW; Wuilleme S; Zweegman S; Kolb B; Touzeau C; Roussel M; Tiab M; Marolleau JP; Meuleman N; Vekemans MC; Westerman M; Klein SK; Levin MD; Fermand JP; Escoffre-Barbe M; Eveillard JR; Garidi R; Ahmadi T; Zhuang S; Chiu C; Pei L; de Boer C; Smith E; Deraedt W; Kampfenkel T; Schecter J; Vermeulen J; Avet-Loiseau H; Sonneveld P
Lancet; 2019 Jul; 394(10192):29-38. PubMed ID: 31171419
[TBL] [Abstract][Full Text] [Related]
8. Subcutaneous Administration of Bortezomib in Combination with Thalidomide and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma Patients.
Wu S; Zheng C; Chen S; Cai X; Shi Y; Lin B; Chen Y
Biomed Res Int; 2015; 2015():927105. PubMed ID: 26425561
[TBL] [Abstract][Full Text] [Related]
9. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study.
Cavo M; Tacchetti P; Patriarca F; Petrucci MT; Pantani L; Galli M; Di Raimondo F; Crippa C; Zamagni E; Palumbo A; Offidani M; Corradini P; Narni F; Spadano A; Pescosta N; Deliliers GL; Ledda A; Cellini C; Caravita T; Tosi P; Baccarani M;
Lancet; 2010 Dec; 376(9758):2075-85. PubMed ID: 21146205
[TBL] [Abstract][Full Text] [Related]
10. Bortezomib and Thalidomide Treatment Results in Newly Diagnosed Transplant-Ineligible Multiple Myeloma Patients are Comparable in Long-Term Follow-Up.
Stork M; Sandecká V; Boichuk I; Adam Z; Krejci M; Brozova L; Sevcikova S; Pour L
Klin Onkol; 2019; 32(6):445-452. PubMed ID: 31842563
[TBL] [Abstract][Full Text] [Related]
11. Bortezomib-cyclophosphamide-dexamethasone (VCD) versus bortezomib-thalidomide-dexamethasone (VTD) -based regimens as induction therapies in newly diagnosed transplant eligible patients with multiple myeloma: a meta-analysis.
Leiba M; Kedmi M; Duek A; Freidman T; Weiss M; Leiba R; Nagler A; Avigdor A
Br J Haematol; 2014 Sep; 166(5):702-10. PubMed ID: 24861981
[TBL] [Abstract][Full Text] [Related]
12. Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial.
Popat R; Brown SR; Flanagan L; Hall A; Gregory W; Kishore B; Streetly M; Oakervee H; Yong K; Cook G; Low E; Cavenagh J;
Lancet Haematol; 2016 Dec; 3(12):e572-e580. PubMed ID: 27843120
[TBL] [Abstract][Full Text] [Related]
13. Combination of bortezomib, thalidomide, and dexamethasone (VTD) as a consolidation therapy after autologous stem cell transplantation for symptomatic multiple myeloma in Japanese patients.
Takashima S; Miyamoto T; Kadowaki M; Ito Y; Aoki T; Takase K; Shima T; Yoshimoto G; Kato K; Muta T; Shiratsuchi M; Takenaka K; Iwasaki H; Teshima T; Kamimura T; Akashi K
Int J Hematol; 2014 Aug; 100(2):159-64. PubMed ID: 24928523
[TBL] [Abstract][Full Text] [Related]
14. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.
Durie BGM; Hoering A; Abidi MH; Rajkumar SV; Epstein J; Kahanic SP; Thakuri M; Reu F; Reynolds CM; Sexton R; Orlowski RZ; Barlogie B; Dispenzieri A
Lancet; 2017 Feb; 389(10068):519-527. PubMed ID: 28017406
[TBL] [Abstract][Full Text] [Related]
15. Randomized phase III trial of consolidation therapy with bortezomib-lenalidomide-Dexamethasone (VRd) vs bortezomib-dexamethasone (Vd) for patients with multiple myeloma who have completed a dexamethasone based induction regimen.
Jacobus SJ; Rajkumar SV; Weiss M; Stewart AK; Stadtmauer EA; Callander NS; Dreosti LM; Lacy MQ; Fonseca R
Blood Cancer J; 2016 Jul; 6(7):e448. PubMed ID: 27471864
[No Abstract] [Full Text] [Related]
16. Real-world outcomes with bortezomib-containing regimens and lenalidomide plus dexamethasone for the treatment of transplant-ineligible multiple myeloma: a multi-institutional report from the Canadian Myeloma Research Group database.
Jimenez-Zepeda VH; Venner C; McCurdy A; Masih-Khan E; Atenafu EG; Sebag M; Stakiw J; Song K; LeBlanc R; Reiman T; Louzada M; Kotb R; Gul E; Reece D
Br J Haematol; 2021 May; 193(3):532-541. PubMed ID: 33559897
[TBL] [Abstract][Full Text] [Related]
17. The impact of induction regimen on transplant outcome in newly diagnosed multiple myeloma in the era of novel agents.
Chakraborty R; Muchtar E; Kumar S; Buadi FK; Dingli D; Dispenzieri A; Hayman SR; Hogan WJ; Kapoor P; Lacy MQ; Leung N; Gertz MA
Bone Marrow Transplant; 2017 Jan; 52(1):34-40. PubMed ID: 27548464
[TBL] [Abstract][Full Text] [Related]
18. [Induction treatment with bortezomib-cyclophosphamide-dexamethasone (CyBorD) for newly diagnosed transplant-eligible patients with multiple myeloma].
Tsukada N; Ikeda M; Shingaki S; Miyazaki K; Meshitsuka S; Yoshiki Y; Abe Y; Suzuki K
Rinsho Ketsueki; 2015 Aug; 56(8):1069-75. PubMed ID: 26345569
[TBL] [Abstract][Full Text] [Related]
19. Treatment Patterns and Clinical and Economic Outcomes in Patients With Newly Diagnosed Multiple Myeloma Treated With Lenalidomide- and/or Bortezomib-containing Regimens Without Stem Cell Transplant in a Real-world Setting.
Chari A; Parikh K; Ni Q; Abouzaid S
Clin Lymphoma Myeloma Leuk; 2019 Oct; 19(10):645-655. PubMed ID: 31377207
[TBL] [Abstract][Full Text] [Related]
20. Treatment Pattern and Outcomes in Newly Diagnosed Multiple Myeloma Patients Who Did Not Receive Autologous Stem Cell Transplantation: A Real-World Observational Study : Treatment pattern and outcomes in patients with multiple myeloma.
He J; Schmerold L; Van Rampelbergh R; Qiu L; Potluri R; Dasgupta A; Li L; Li Y; Hu P; Nemat S; Smugar SS; Zeltzer P; Appiani C; Li Q; Mehra M; Richarz U
Adv Ther; 2021 Jan; 38(1):640-659. PubMed ID: 33211297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]